207 related articles for article (PubMed ID: 27550486)
1. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
3. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
4. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
6. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
7. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
8. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study.
Bankar A; Chan WC; Liu N; Cheung M; Alibhai S; Gupta V
Blood Adv; 2023 Sep; 7(17):5014-5026. PubMed ID: 37184988
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.
Johansson P
Semin Thromb Hemost; 2006 Apr; 32(3):171-3. PubMed ID: 16673273
[TBL] [Abstract][Full Text] [Related]
11. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
Price GL; Davis KL; Karve S; Pohl G; Walgren RA
PLoS One; 2014; 9(3):e90299. PubMed ID: 24618579
[TBL] [Abstract][Full Text] [Related]
12. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
Cervantes F; Tassies D; Salgado C; Rovira M; Pereira A; Rozman C
Acta Haematol; 1991; 85(3):124-7. PubMed ID: 2042444
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Kutti J; Ridell B
Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
[TBL] [Abstract][Full Text] [Related]
14. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
[TBL] [Abstract][Full Text] [Related]
15. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Rukavitsyn OA; Pop VP; Seriakov AP
Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
[TBL] [Abstract][Full Text] [Related]
16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
17. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
[TBL] [Abstract][Full Text] [Related]
18. Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.
Benton CB; Tanaka M; Wilson C; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2015 Apr; 39(4):419-23. PubMed ID: 25687833
[TBL] [Abstract][Full Text] [Related]
19. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of myeloproliferative neoplasms in the United States.
Mehta J; Wang H; Iqbal SU; Mesa R
Leuk Lymphoma; 2014 Mar; 55(3):595-600. PubMed ID: 23768070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
